天冬氨酸转氨酶/丙氨酸转氨酶(DeRitis)比值可预测左心室辅助装置植入术后中期死亡及肾脏与呼吸功能障碍
该回顾性分析纳入2012年1月至2014年8月在本中心接受左心室辅助装置(LVAD)植入的63例患者,主要终点为术后180天生存。结果显示天冬氨酸转氨酶、MELD评分及DeRitis比值(DRR)在180天非生存者中显著高于生存者,DRR>1.37是30天和180天死亡的独立预测因子,并与术后需肾脏替代治疗的急性肾损伤及延长通气时间相关。作者认为DRR应纳入术前风险分层与患者选择。
要点
- 180天非生存者天冬氨酸转氨酶、MELD评分及DRR均显著高于生存者。
- DRR>1.37是30天死亡(OR 4.5)和180天死亡(OR 4.1)的独立预测因子。
- DRR与术后需肾脏替代治疗的急性肾损伤(OR 4.2)及通气时间>72小时(OR 3.8)相关。
核心结论
- DRR可预测LVAD植入患者的早期和中期死亡及重要并发症。
- 作者认为DRR应纳入LVAD植入的术前风险分层和患者选择。
研究设计与样本
- 回顾性分析2012年1月至2014年8月在本中心接受LVAD植入的所有患者,共63例,主要终点为术后180天生存。
- 患者平均年龄59.9±8.3岁,50%为男性,术前平均射血分数16.3±7.7,13例需术前肾脏替代治疗,9例使用体外生命支持。
- 平均Interagency Registry for Mechanically Assisted Circulatory Support分级为2.8±1.3,术前平均MELD为12.7±7.2,术前平均DRR为2.01±4.4。
主要发现
- 180天非生存者天冬氨酸转氨酶为102±220.8 U/l,生存者为57.8±123.4 U/l,非生存者显著高于生存者(P=0.041)。
- 180天非生存者MELD评分为16.1±8.8,生存者为11.4±6.1,非生存者显著高于生存者(P=0.017)。
- 180天非生存者DRR为4.2±7.8,生存者为1.1±1.1,非生存者显著高于生存者(P=0.001)。
- 逻辑回归分析显示DRR>1.37是30天死亡(OR 4.5)和180天死亡(OR 4.1)的独立预测因子。
- DRR与术后需肾脏替代治疗的急性肾损伤(OR 4.2)及术后通气时间>72小时(OR 3.8)相关。
关键数值与推荐
- DRR>1.37为30天死亡(OR 4.5)和180天死亡(OR 4.1)的独立预测因子。
- DRR对180天死亡的敏感度为0.80、特异度为0.81,曲线下面积0.834,截断值1.37。
临床怎么用
- 作者认为DRR应纳入LVAD植入的术前风险分层和患者选择。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: Preoperative liver dysfunction is a well-known risk factor for adverse events after major surgery. However, there is only little data regarding the precise role of the Model of End-Stage Liver Disease (MELD) score and the De Ritis ratio (DRR, alanine transaminase/aspartate aminotransferase) as a predictor for outcome after left ventricular assist device (LVAD) implantation. METHODS: A retrospective analysis of all patients undergoing LVAD implantation at our institution between January 2012 and August 2014 was performed. The primary outcome was survival at 180 days after surgery. RESULTS: During the observation period, 63 patients underwent LVAD implantation (mean age 59.9 ± 8.3 years, 50% male). Mean preoperative ejection fraction was 16.3 ± 7.7, 13 patients required preoperative renal replacement therapy and 9 patients were on extracorporeal life support. Mean Interagency Registry for Mechanically Assisted Circulatory Support level was 2.8 ± 1.3, mean preoperative MELD was 12.7 ± 7.2, mean preoperative DRR was 2.01 ± 4.4. Aspartate aminotransferase (102 ± 220.8 vs 57.8 ± 123.4 U/l, P = 0.041), MELD score (16.1 ± 8.8 vs 11.4 ± 6.1, P = 0.017) and DRR (4.2 ± 7.8 vs 1.1 ± 1.1, P = 0.001) were significantly higher in non-survivors than in survivors after 180 days. Using logistic regression analyses, a DRR >1.37 was an independent predictor for 30-day mortality [odds ratio (OR) 4.5] and 180-day mortality (OR 4.1). In addition, the DRR was associated with postoperative acute kidney injury with need for renal replacement therapy (OR 4.2) and prolonged postoperative ventilation time >72 h (OR 3.8). Using receiver operator characteristics analyses, DRR showed a sensitivity of 0.80 and a specificity of 0.81 (area under the curve 0.834, cut-off 1.37) for 180-day mortality. CONCLUSIONS: The DRR is predictive of early and mid-term mortality as well as relevant morbidities in patients undergoing LVAD implantation. Therefore, the DRR should be considered within the preoperative risk stratification and patient selection for LVAD implantation.
引用
- Pilarczyk K, Carstens H, Heckmann J, et al. The aspartate transaminase/alanine transaminase (DeRitis) ratio predicts mid-term mortality and renal and respiratory dysfunction after left ventricular assist device implantation. Eur J Cardiothorac Surg. 2017. PMID: 29156019. doi:10.1093/ejcts/ezx247
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。